SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Reviewed

Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, Taiji M.

American Journal of Physiology Renal Physiology   Vol. 289 ( 5 ) page： F998 - F1004   2005

DSP-0692, a selective SCD inhibitor, enhances the anti-tumor activity of anti-PD1 antibody

Eiji Sugaru, Yudai Furuta, Yoshikazu Nagagaki, Satoshi Ikeda, Yuichi Fukunaga, Hiroki Umehara, Tsuguteru Otsubo, Manabu Watanabe, Shingo Tojo, Miki Hashizume, Yasushi Matsuki, and Hitoshi Ban

Cancer Res.   Vol. 79 ( 13 Supplement ) page： 3595 - 3595   2019.7

Antibody intracellular activated drug conjugate (AiADC) as novel ADC technology

Atsushi Suwa, Kazuo Komiya, Kenta Kadotsuji, Shoko Ochiai, Yosuke Takanashi, Eiji Sugaru, and Hitoshi Ban

Cancer Res.   Vol. 79 ( 13 Supplement ) page： 223 - 223   2019.7

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Reviewed

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget.   Vol. 7 ( 13 ) page： 17035 - 17046   2016.3

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Reviewed

Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, Yamamoto S, Robinson DT, Li CJ.

Cancer Immunol Immunother.   Vol. 64 ( 10 ) page： 1229 - 1239   2015.10

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability. Reviewed

Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Umezome T, Sakurai Y, Sawada N, Tadano J, Sugaru E, Ono M, Hirose Y, Nakahira H.

Bioorg Med Chem.   Vol. 23 ( 4 ) page： 779 - 790   2015.2

2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): A potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. Reviewed

Nishio Y, Kimura H, Sawada N, Sugaru E, Horiguchi M, Ono M, Furuta Y, Sakai M, Masui Y, Otani M, Hashizuka T, Honda Y, Deguchi J, Nakagawa T, Nakahira H.

Med Chem.   Vol. 19 ( 18 ) page： 5490 - 5499   2011.9

Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Reviewed

Nishio Y, Kimura H, Tosaki S, Sugaru E, Sakai M, Horiguchi M, Masui Y, Ono M, Nakagawa T, Nakahira H.

Bioorg Med Chem.   Vol. 20 ( 24 ) page： 7246 - 7249   2010.12

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. Reviewed

Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, Masui Y, Tsuchida A, Sato Y, Takubo K, Hochigai H, Kimura H, Nakahira H, Nakagawa T, Taiji M.

Diabetes Obes Metab.   Vol. 12 ( 5 ) page： 421 - 430   2010.5

Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats. Reviewed

Tsujimura T, Nagamine J, Sugaru E, Ono-Kishino M, Tokunaga T, Kitoh M, Nagata R, Nakagawa T, Taiji M.

Biol Pharm Bull.   Vol. 32 ( 12 ) page： 1991 - 1996   2009.12

The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters. Reviewed

Tsujimura T, Ono-Kishino M, Nagamine J, Sugaru E, Tokunaga T, Kitoh M, Nagata R, Nakagawa T, Taiji M.

Biomed Res.   Vol. 30 ( 3 ) page： 177 - 182   2009

Chronic administration of SMP-534 ameliorates renal dysfunction in 5/6 nephrectomized rats. Reviewed

Tsujimura T, Nagamine J, Sugaru E, Nakagawa T, Ono-Kishino M, Tokunaga T, Kitoh M, Nagata R, Taiji M.

Nephron Exp Nephrol.   Vol. 110 ( 4 ) page： e99 - e108   2008

Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Reviewed

Yamanaka M, Tsuchida A, Nakagawa T, Nonomura T, Ono-Kishino M, Sugaru E, Noguchi H, Taiji M

Diabetes, Obesity and Metabolism   Vol. 9 ( 1 ) page： 59 - 64   2007

Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Reviewed

Tsuchida A, Nonomura T, Nakagawa T, Itakura Y, Ono-Kishino M, Yamanaka M, Sugaru E, Taiji M, Noguchi H.

Diabetes, Obesity and Metabolism   Vol. 4 ( 4 ) page： 262 - 269   2002

Brain-derived neurotrophic factor improved insulin sensitivity in obese fatty (fa/fa) Zucker rats. Reviewed

Nakagawa T, Sugaru E, Taiji M.

Biomedical Research   Vol. 23 ( 1 ) page： 11 - 15   2002

Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Reviewed

Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H.

Diabetes Metabolism Research Review   Vol. 18 ( 3 ) page： 185 - 191   2002

Unidirectional transport from apical to basolateral compartment of cobalt ion in polarized Madin-Darby canine kidney cells. Reviewed

Nagao M, Sugaru E, Kambe T, Sasaki R.

Biochemical and Biophysical Research Communications   Vol. 257 ( 2 ) page： 289 - 294   1999